272-67-3 | Thieno[3,2-b]pyridine

Packsize	Purity	Availability	Price	Discounted Price
250mg	98%	in stock	$22.00	$16.00
1g	98%	in stock	$57.00	$40.00

Description

• Catalog Number: AF32744
• Chemical Name: Thieno[3,2-b]pyridine
• CAS Number: 272-67-3
• Molecular Formula: C7H5NS
• Molecular Weight: 135.1863
• MDL Number: MFCD11110437
• SMILES: c1cnc2c(c1)scc2

Computed Properties

• Complexity: 105
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 9
• Hydrogen Bond Acceptor Count: 2
• XLogP3: 2

Literature

• Discovery and structure-activity relationships study of novel thieno[2,3-b]pyridine analogues as hepatitis C virus inhibitors.

  Bioorganic & medicinal chemistry letters 20140315

• Structural requirements of pyrimidine, thienopyridine and ureido thiophene carboxamide-based inhibitors of the checkpoint kinase 1: QSAR, docking, molecular dynamics analysis.

  Journal of molecular modeling 20120701

• Duration of dual antiplatelet therapy and long-term clinical outcome after coronary drug-eluting stent implantation: landmark analyses from the CREDO-Kyoto PCI/CABG Registry Cohort-2.

  Circulation. Cardiovascular interventions 20120601

• Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families.

  Bioorganic & medicinal chemistry letters 20120501

• Lack of association between serum paraoxonase-1 activity and residual platelet aggregation during dual anti-platelet therapy.

  Thrombosis research 20120401

• Aminodi(hetero)arylamines in the thieno[3,2-b]pyridine series: synthesis, effects in human tumor cells growth, cell cycle analysis, apoptosis and evaluation of toxicity using non-tumor cells.

  Molecules (Basel, Switzerland) 20120328

• Outcomes of patients treated with triple antithrombotic therapy after primary percutaneous coronary intervention for ST-elevation myocardial infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction [HORIZONS-AMI] trial).

  The American journal of cardiology 20120315

• Preoperative thienopyridine use and outcomes after surgery: a systematic review.

  The American journal of medicine 20120101

• A meta-analysis of randomized controlled trials appraising the efficacy and safety of cilostazol after coronary artery stent implantation.

  Cardiology 20120101

• Rivaroxaban (Xarelto) for acute coronary syndrome.

  The Medical letter on drugs and therapeutics 20111212

• Anti-hepatocellular carcinoma activity using human HepG2 cells and hepatotoxicity of 6-substituted methyl 3-aminothieno[3,2-b]pyridine-2-carboxylate derivatives: in vitro evaluation, cell cycle analysis and QSAR studies.

  European journal of medicinal chemistry 20111201

• Impact of smoking on outcomes of patients with ST-segment elevation myocardial infarction (from the HORIZONS-AMI Trial).

  The American journal of cardiology 20111115

• Determinants of intracranial hemorrhage incidence in patients on oral anticoagulation followed at the Lahey clinic.

  Journal of thrombosis and thrombolysis 20111001

• Thienopyridine-associated drug-drug interactions: pharmacologic mechanisms and clinical relevance.

  Current cardiology reports 20111001

• Management of antiplatelet therapy inpatients at risk for coronary StentThrombosis undergoing non-cardiac surgery.

  Drugs 20111001

• Regulation of folding and photochromic reactivity of terarylenes through a host-guest interaction.

  Chemistry (Weinheim an der Bergstrasse, Germany) 20110919

• Design and synthesis of some new thiophene, thienopyrimidine and thienothiadiazine derivatives of antipyrine as potential antimicrobial agents.

  European journal of medicinal chemistry 20110901

• Focused clinical review: periprocedural management of antiplatelet therapy in patients with coronary stents.

  Heart, lung & circulation 20110701

• [ADP receptor blockers: new insights in the therapy and prophylaxis of ischemic heart disease].

  Deutsche medizinische Wochenschrift (1946) 20110701

• Synthesis and pharmacological evaluation of thieno[2,3-b]pyridine derivatives as novel c-Src inhibitors.

  Bioorganic & medicinal chemistry 20110415

• Morbidity associated with three different antiplatelet regimens in patients undergoing implantation of cardiac rhythm management devices.

  Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 20110301

• Combination of low-dose aspirin and thienopyridine exacerbates small bowel injury.

  Scandinavian journal of gastroenterology 20110301

• Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes.

  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20110101

• Ticagrelor: a novel reversible oral antiplatelet agent.

  Cardiology in review 20110101

• ChemT, an open-source software for building template-based chemical libraries.

  SAR and QSAR in environmental research 20110101

• Efficient synthesis of 6-(hetero)arylthieno[3,2-b]pyridines by Suzuki-Miyaura coupling. Evaluation of growth inhibition on human tumor cell lines, SARs and effects on the cell cycle.

  European journal of medicinal chemistry 20101201

• Novel 6-[(hetero)arylamino]thieno[3,2-b]pyridines: synthesis and antitumoral activities.

  European journal of medicinal chemistry 20101201

• [ST-elevation myocardial infarction: reperfusion strategy based on the results from large clinical trials].

  Giornale italiano di cardiologia (2006) 20101001

• New insight in antiplatelet therapy monitoring in cardiovascular patients: from aspirin to thienopyridine.

  Cardiovascular & hematological disorders drug targets 20100901

• Controversies in oral antiplatelet therapy in patients undergoing aortocoronary bypass surgery.

  The Annals of thoracic surgery 20100901

• Letter by Potter and Le Lorier regarding article, 'Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome'.

  Circulation 20100803

• Predictors of embolization during protected renal artery angioplasty and stenting: Role of antiplatelet therapy.

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20100701

• Antiplatelet therapy in percutaneous coronary intervention: recent advances in oral antiplatelet agents.

  Current opinion in cardiology 20100701

• Preventing serious sequelae after an acute coronary syndrome: the consequences of thrombosis versus bleeding with antiplatelet therapy.

  Journal of cardiovascular pharmacology 20100601

• Biotransformation of prasugrel, a novel thienopyridine antiplatelet agent, to the pharmacologically active metabolite.

  Drug metabolism and disposition: the biological fate of chemicals 20100601

• [Does dual antiplatelet therapy always require gastroprotection? Tailored medical therapy should prevail over the generalized prescription of proton pump inhibitors in patients on dual antiplatelet therapy].

  Giornale italiano di cardiologia (2006) 20100601

• Impact of anticoagulant therapy with dual antiplatelet therapy on prognosis after treatment with drug-eluting coronary stents.

  Journal of cardiology 20100501

• Addition of cilostazol to aspirin and a thienopyridine for prevention of restenosis after coronary artery stenting: a meta-analysis.

  Journal of clinical pharmacology 20100401

• Impact of high-responsiveness to dual antiplatelet therapy on bleeding complications in patients receiving drug-eluting stents.

  Circulation journal : official journal of the Japanese Circulation Society 20100401

• Inhibition of eEF2-K by thieno[2,3-b]pyridine analogues.

  Bioorganic & medicinal chemistry letters 20100401

• Genotyping, clopidogrel metabolism, and the search for the therapeutic window of thienopyridines.

  Circulation 20100202

• Combination antithrombotic therapies.

  Circulation 20100202

• Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans.

  Journal of clinical pharmacology 20100201

• Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases.

  British journal of pharmacology 20100201

• Perioperative management of patients with drug-eluting stents.

  JACC. Cardiovascular interventions 20100201

• Reducing cardiac ischemic events in patients with ACS: prasugrel versus clopidogrel. Commentary.

  Postgraduate medicine 20100101

• Triple antithrombotic therapy with aspirin, a thienopyridine derivative plus oral anticoagulation in patients with atrial fibrillation undergoing coronary stenting.

  Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese 20100101

• Platelet P2Y₁₂ receptor inhibition: an update on clinical drug development.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20100101

• [Thienopyridines in the treatment and prevention of cardiovascular diseases. Part V. Combination of clopidogrel and acetylsalicylic acid in the treatment of stable patients with atherothrombotic cardiovascular diseases].

  Kardiologiia 20100101

• N3-arylmalonamides: a new series of thieno[3,2-b]pyridine based inhibitors of c-Met and VEGFR2 tyrosine kinases.

  Bioorganic & medicinal chemistry letters 20091215

• Clinical trial update II: TRITON-TIMI 38 provides reassurance on concomitant use of proton pump inhibitors and thienopyridines.

  European heart journal 20091201

• Balancing thromboembolism and bleeding risks: insights from anticoagulation for prosthetic heart valves.

  Chest 20091201

• Comparison of ticagrelor and thienopyridine P2Y(12) binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis.

  Thrombosis research 20091101

• A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel.

  Drug metabolism and disposition: the biological fate of chemicals 20091101

• Antiplatelet therapy after coronary intervention in Asia and Japan: the Asian perspective of antiplatelet intervention.

  Hamostaseologie 20091101

• 2D 1H and 13C NMR conformational studies of thienopyridines and carboline biarylic compounds.

  Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy 20091001

• Risk of combining PPIs with thienopyridines: fact or fiction?

  Lancet (London, England) 20090919

• Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials.

  Lancet (London, England) 20090919

• Thienopyridine therapy and risk for cardiovascular events in secondary prevention.

  Current atherosclerosis reports 20090901

• Platelet P2Y12 receptor inhibition by thienopyridines: status and future.

  Expert opinion on investigational drugs 20090901

• Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor.

  Pharmacotherapy 20090901

• Emergence of the concept of platelet reactivity monitoring of response to thienopyridines.

  Heart (British Cardiac Society) 20090801

• Impact of thienopyridine administration prior to primary stenting in acute myocardial infarction.

  Journal of interventional cardiology 20090801

• Effects of gastric medicines on gastroduodenal injury in patients with stable angina during antiplatelet therapy.

  Journal of cardiology 20090801

• P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use.

  European heart journal 20090801

• ADP receptor-blocker thienopyridines: chemical structures, mode of action and clinical use. A review.

  The Journal of invasive cardiology 20090801

• Drug-specific thienopyridine resistance in patient with recurrent coronary stent thrombosis.

  The Journal of invasive cardiology 20090801

• Test before you stop.

  Archives of surgery (Chicago, Ill. : 1960) 20090801

• Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials.

  EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 20090801

• Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial.

  Journal of the American College of Cardiology 20090728

• Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.

  Lancet (London, England) 20090704

• A new generation of antiplatelet agents.

  Current opinion in cardiology 20090701

• Tricyclic thienopyridine-pyrimidones/thienopyrimidine-pyrimidones as orally efficacious mGluR1 antagonists for neuropathic pain.

  Bioorganic & medicinal chemistry letters 20090615

• Update on dual antiplatelet therapy for percutaneous coronary intervention.

  Heart (British Cardiac Society) 20090601

• Developments in antiplatelet therapy for acute coronary syndromes and considerations for long-term management.

  Current medical research and opinion 20090601

• Future of oral antiplatelet therapy: four challenged hypotheses.

  Thrombosis and haemostasis 20090601

• Platelet perturbations in diabetes: implications for cardiovascular disease risk and treatment.

  Expert review of cardiovascular therapy 20090501

• Prasugrel: newest antiplatelet agent and its emerging role in management of acute coronary syndrome and percutaneous coronary intervention.

  Future cardiology 20090501

• Beyond platelet inhibition: potential pleiotropic effects of ADP-receptor antagonists.

  Journal of thrombosis and thrombolysis 20090401

• Safety of short-term discontinuation of antiplatelet therapy in patients with drug-eluting stents.

  Circulation 20090331

• Identification of a selective thieno[2,3-c]pyridine inhibitor of COT kinase and TNF-alpha production.

  Bioorganic & medicinal chemistry letters 20090315

• Antiplatelet therapy for improving post-PCI outcomes: interpreting current treatment guidelines for optimal management of the post-ACS patient.

  The American journal of managed care 20090301

• Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation.

  Circulation 20090224

• Increased plasma membrane expression of human follicle-stimulating hormone receptor by a small molecule thienopyr(im)idine.

  Molecular and cellular endocrinology 20090127

• Antiplatelet agents in the perioperative period.

  Archives of surgery (Chicago, Ill. : 1960) 20090101

• Antithrombotic treatment before and after peripheral artery percutaneous angioplasty.

  Blood transfusion = Trasfusione del sangue 20090101

• [Thienopyridines in the treatment and prevention of cardiovascular diseases. Part I. Ticlopidine].

  Kardiologiia 20090101

• [Thienopyridines in the treatment and prevention of cardiovascular diseases. Part II. Clinical pharmacology of clopidogrel].

  Kardiologiia 20090101

• [Thienopyridines in the treatment and prevention of cardiovascular diseases. III. therapeutic application of clopidogrel as monotherapy (without acetylsalicylic acid)].

  Kardiologiia 20090101

• [Controversy regarding the concomitant use of clopidogrel and proton pump inhibitors (PPI)].

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20090101

• Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo.

  Journal of the American College of Cardiology 20081209

• The pursuit of clinically relevant measures of platelet function after antiplatelet drug therapy.

  Journal of the American College of Cardiology 20081209

• Incidence of bleeding and compliance on prolonged dual antiplatelet therapy (aspirin + thienopyridine) following drug-eluting stent implantation.

  The American journal of cardiology 20081201

• Antiplatelet therapy use after discharge among acute myocardial infarction patients with in-hospital bleeding.

  Circulation 20081118

• Resistance to aspirin and thienopyridines in diabetes mellitus and metabolic syndrome.

  Current vascular pharmacology 20081001

• Status of drug-eluting coronary stents.

  Medicine and health, Rhode Island 20081001

• Antibacterial profile against drug-resistant Staphylococcus epidermidis clinical strain and structure-activity relationship studies of 1H-pyrazolo[3,4-b]pyridine and thieno[2,3-b]pyridine derivatives.

  Bioorganic & medicinal chemistry 20080901

• Determining the efficacy of antiplatelet therapies for the individual: lessons from clinical trials.

  Journal of thrombosis and thrombolysis 20080801

• Thrombocytopenia in patients treated with heparin, combination antiplatelet therapy, and intra-aortic balloon pump counterpulsation.

  Journal of interventional cardiology 20080801

• New antiplatelet therapies in development.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20080701

• Benefits and limitations of current antiplatelet therapies.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20080701

• The evolution of thienopyridine therapy clopidogrel duration, diabetes, and drug-eluting stents.

  Journal of the American College of Cardiology 20080610

• Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

  Chest 20080601

• Antiplatelet drugs in cardiological practice: established strategies and new developments.

  Vascular health and risk management 20080601

• Review of the 2005 American College of Cardiology, American Heart Association, and Society for Cardiovascular Interventions guidelines for adjunctive pharmacologic therapy during percutaneous coronary interventions: practical implications, new clinical data, and recommended guideline revisions.

  American heart journal 20080501

• The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary intervention.

  Clinical cardiology 20080301

• 'Triple therapy' or triple threat? Balancing the risks of antithrombotic therapy for patients with atrial fibrillation and coronary stents.

  Journal of the American College of Cardiology 20080226

• A selective phosphatase of regenerating liver phosphatase inhibitor suppresses tumor cell anchorage-independent growth by a novel mechanism involving p130Cas cleavage.

  Cancer research 20080215

• Bleeding events with antithrombotic therapy in patients with unstable angina or non-ST-segment elevation myocardial infarction; insights from a large clinical practice registry (GRACE).

  Heart, lung & circulation 20080201

• [Medical treatment of patients with clinical peripheral arterial disease at hospital discharge: compliance with the French guidelines and changing practices (COPART I registry)].

  Journal des maladies vasculaires 20080201

• ST-elevation myocardial infarction: the role of adjunctive antiplatelet therapy.

  The American journal of emergency medicine 20080201

• Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans.

  Journal of clinical pharmacology 20080101

• Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine.

  Drug metabolism and pharmacokinetics 20080101

• Synthesis and biological evaluation of thieno[2,3-d]pyrimidine derivatives for anti-inflammatory, analgesic and ulcerogenic activity.

  Acta pharmaceutica (Zagreb, Croatia) 20071201

• [Prescription, monitoring of antithrombotic treatment: 1--antiplatelet agents].

  La Revue du praticien 20071130

• Defining the mechanism of activation of AMP-activated protein kinase by the small molecule A-769662, a member of the thienopyridone family.

  The Journal of biological chemistry 20071109

• Efficacy and safety of triple antiplatelet therapy with and without concomitant anticoagulation during elective percutaneous coronary intervention (the REMOVE trial).

  The American journal of cardiology 20071001

• Triple therapy of warfarin, aspirin and a thienopyridine for patients treated with vitamin K antagonists undergoing coronary stenting. A review of the evidence.

  Internal and emergency medicine 20071001

• Platelet function testing and cardiovascular outcomes: steps forward in identifying the best predictive measure.

  Thrombosis and haemostasis 20071001

• Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project.

  Journal of the American College of Cardiology 20070918

• Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment.

  Circulation 20070814

• Drug-eluting stents: dual antiplatelet therapy for every survivor?

  Circulation 20070814

• Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial.

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20070701

• The disposition of prasugrel, a novel thienopyridine, in humans.

  Drug metabolism and disposition: the biological fate of chemicals 20070701

• Absorption, distribution and excretion of the new thienopyridine agent prasugrel in rats.

  Xenobiotica; the fate of foreign compounds in biological systems 20070701

• Neutropenia in patients treated with thienopyridines and high-dose oral prednisone after percutaneous coronary interventions.

  Journal of interventional cardiology 20070601

• Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians.

  Journal of the American Dental Association (1939) 20070501

• Oral antiplatelet therapy for percutaneous coronary revascularization.

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20070401

• Antithrombotic treatment for peripheral arterial disease.

  Heart (British Cardiac Society) 20070301

• Thienopyridine urea inhibitors of KDR kinase.

  Bioorganic & medicinal chemistry letters 20070301

• Discovery of thienopyridines as Src-family selective Lck inhibitors.

  Bioorganic & medicinal chemistry letters 20070301

• Thienopyridines in cardiovascular disease: focus on clopidogrel resistance.

  Thrombosis and haemostasis 20070301

• Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians.

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20070215

• Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians.

  Circulation 20070213

• Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians.

  Journal of the American College of Cardiology 20070213

• [Update on antithrombotic treatments in arterial diseases].

  Revue medicale suisse 20070207

• Prasugrel.

  Expert opinion on investigational drugs 20061201

• Short-term triple therapy with aspirin, warfarin, and a thienopyridine among patients undergoing percutaneous coronary intervention.

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20060701

• Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.

  Circulation 20060620

• Mechanisms of action and targets for actual and future antiplatelet drugs.

  Mini reviews in medicinal chemistry 20060601

• Aspirin, warfarin and a thienopyridine for acute coronary syndromes.

  Cardiology 20060101

• Drawbacks of nonrandomized trials in acute coronary syndromes.

  The American journal of cardiology 20060101

• Thienopyridines and statins: assessing a potential drug-drug interaction.

  Current pharmaceutical design 20060101

• Clinical applications of antiplatelet therapy.

  Reviews in cardiovascular medicine 20060101

• Optimizing antiplatelet therapy for the ACS patient: reacting to clinical trial data from the ISAR-REACT-2 studies.

  Reviews in cardiovascular medicine 20060101

• Evolving antithrombotic treatment strategies for acute ST-elevation myocardial infarction.

  Reviews in cardiovascular medicine 20060101

• Treating patients with acute coronary syndromes with aggressive antiplatelet therapy (from the Global Registry of Acute Coronary Events).

  The American journal of cardiology 20051001

• Early discharge using five french guiding catheter for transfemural coronary stenting: a feasibility and safety study (EDU 5Fr study).

  The American journal of cardiology 20050915

• Therapeutic approaches in arterial thrombosis.

  Journal of thrombosis and haemostasis : JTH 20050801

• [Recurrent hemoptysis following thienopyridines and amiodarone administration. therapeutic dilemma].

  Polskie Archiwum Medycyny Wewnetrznej 20050801

• Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial.

  Circulation 20050628

• Validation of predictors of intraprocedural stent thrombosis in the drug-eluting stent era.

  The American journal of cardiology 20050615

• Cardiovascular risk prevention in peripheral artery disease.

  Journal of vascular surgery 20050601

• The platelet P2 receptors in thrombosis.

  Seminars in thrombosis and hemostasis 20050401

• Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis.

  Seminars in thrombosis and hemostasis 20050401

• Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity.

  Seminars in thrombosis and hemostasis 20050401

• Preclinical and clinical studies with selective reversible direct P2Y12 antagonists.

  Seminars in thrombosis and hemostasis 20050401

• Endothelial action of thienopyridines and thienopyrimidinones in the isolated guinea pig heart.

  Prostaglandins, leukotrienes, and essential fatty acids 20050201

• Predictive value of plasma plasminogen activator inhibitor-1 for coronary restenosis: dependence on stent implantation and antithrombotic medication.

  Journal of thrombosis and haemostasis : JTH 20050201

• Optimal antithrombotic treatment for percutaneous coronary intervention.

  Minerva cardioangiologica 20050201

• Drug therapy during percutaneous coronary interventions in stable and unstable coronary artery disease: the Italian Drug Evaluation in Angioplasty (IDEA) study.

  Italian heart journal : official journal of the Italian Federation of Cardiology 20050201

• Is platelet adhesion assay able to quantify drug-induced platelet dysfunction?

  Seminars in thrombosis and hemostasis 20050101

• Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.

  Circulation 20040921

• The role of platelet inhibition in the drug-eluting stent era.

  Coronary artery disease 20040901

• Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

  Chest 20040901

• Thienopyridine and benzofuran derivatives as potent anti-tumor agents possessing different structure-activity relationships.

  Bioorganic & medicinal chemistry letters 20040705

• Acute coronary syndromes in women: is treatment different? Should it be?

  Current cardiology reports 20040701

• Current concepts in the antithrombotic management of non-ST-elevation acute coronary syndromes.

  Current cardiology reports 20040701

• Paclitaxel-eluting coronary stents.

  The New England journal of medicine 20040513

• Antiplatelet therapy in cardiovascular disease.

  Postgraduate medical journal 20040301

• Underuse of aspirin in type 2 diabetes mellitus: prevalence and correlates of therapy in rural Canada.

  Clinical therapeutics 20040301

• Platelet ADP receptor antagonists: ticlopidine and clopidogrel.

  Best practice & research. Clinical haematology 20040301

• Antiplatelet agents.

  The hematology journal : the official journal of the European Haematology Association 20040101

• Clopidogrel's role in the management of atherosclerotic disease: a focus on acute coronary syndromes.

  Expert review of cardiovascular therapy 20031101

• The expanding role of antiplatelet agents in coronary artery disease. A current review of aspirin, glycoprotein IIb/IIIa inhibitors, and the thienopyridines.

  Minerva cardioangiologica 20031001

• Clinical outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting.

  Journal of the American College of Cardiology 20030716

• Role of antiplatelet drugs in the prevention of cardiovascular events.

  Thrombosis research 20030615

• [Premedication by thienopyridine before percutaneous coronary interventions in unstable angina].

  Annales de cardiologie et d'angeiologie 20030601

• Going with the flow of anticoagulant therapy.

  Nursing 20030301

• Contemporary view of the acute coronary syndromes.

  The Journal of invasive cardiology 20030201

• ADP receptors--targets for developing antithrombotic agents.

  Current pharmaceutical design 20030101

• Consensus on anti-platelet therapy in peripheral arterial disease: saving lives and limbs.

  Platelets 20030101

• Platelets: is aspirin sufficient or must we know how to pronounce abciximab?

  Seminars in vascular surgery 20021201

• The first orally active low molecular weight agonists for the LH receptor: thienopyr(im)idines with therapeutic potential for ovulation induction.

  Chembiochem : a European journal of chemical biology 20021004

• The thienopyridines.

  Journal of interventional cardiology 20020201

• Clopidogrel and percutaneous coronary intervention.

  Lancet (London, England) 20020112

• A guide to drug use during percutaneous coronary intervention.

  Drugs 20020101

• Pharmacogenetics of antiplatelet drugs.

  TheScientificWorldJournal 20020101